What is Celcuity?
Celcuity is a clinical-stage biotechnology firm dedicated to enhancing cancer patient survival through a dual approach of integrated therapeutics and companion diagnostics. The company's therapeutic development focuses on in-licensing and advancing molecularly targeted therapies that align with the cancer drivers identified by its companion diagnostics. The proprietary CELsignia companion diagnostic platform is designed to analyze live patient tumor cells, enabling the identification of new patient populations who are likely to respond to existing targeted therapies. This innovative strategy positions Celcuity at the forefront of personalized cancer treatment.
How much funding has Celcuity raised?
Celcuity has raised a total of $117.5M across 6 funding rounds:
Multiple Rounds
$31.1M
Debt
$350K
Stock Offering
$24M
Debt
$62M
Debt (2017): $5.8M, investors not publicly disclosed
Debt (2017): $2.6M, investors not publicly disclosed
Stock Issuance/Offering (2017): $22.8M, investors not publicly disclosed
Debt (2020): $350K featuring PPP
Stock Issuance/Offering (2021): $24M backed by Craig-Hallum Capital Group
Debt (2024): $62M with participation from Oxford Finance
Key Investors in Celcuity
Oxford Finance
Oxford Finance, founded in 2002 and headquartered in Alexandria, Virginia, is a specialty finance firm that offers flexible financial solutions to healthcare and life sciences companies worldwide.
Craig-Hallum Capital Group
Craig-Hallum Capital Group is an investment bank that provides financial advisory and capital raising services, often focusing on growth-stage companies in various sectors.
PPP
Public-Private Partnership
What's next for Celcuity?
The recent major strategic investment signifies a critical juncture for Celcuity, likely enabling the company to accelerate its therapeutic pipeline development and expand the reach of its CELsignia platform. This capital infusion is expected to fuel further clinical trials, enhance manufacturing capabilities, and potentially support strategic partnerships or acquisitions. As a clinical-stage biotechnology company, Celcuity's trajectory will be closely watched by investors and the medical community, with a focus on its ability to translate diagnostic insights into tangible patient benefits and commercial success.
See full Celcuity company page
